$PALI

Baltera Robert Jr. purchased $102K of PALI

Baltera Robert Jr. purchased 50,000 shares of PALISADE BIO, INC. (PALI) at an average of $2.04 ($2.03–$2.05, $0.10M total) across 2 trades over 2026-07-06 to 2026-07-07.

Original reporting
SEC EDGAR · Baltera Robert Jr.
Published Jul 8, 2026, 10:56 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PALI
Bullish
medium confidence
Mentioned
$PALI
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PALIBullishLow
01

Why it matters

The only new information is the director’s open-market purchase size, price range, and post-transaction holdings; it does not change fundamentals on its own.

02

Market read

Traders may treat the filing as a small sentiment input, but it is unlikely to drive a durable repricing without additional company catalysts.

03

What to watch

The article does not state whether the director’s purchase is part of a broader pattern, nor does it include any accompanying company news that would validate a bullish thesis.

Relevance 5/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-08)

Background

The article is an SEC Form 4 insider transaction disclosure for Palisade Bio, Inc.

Company-level read

Ticker impact

$PALIBullishMedium confidence
Context

SEC Form 4 shows director Baltera Robert Jr. bought 50,000 shares of Palisade Bio at about $2.04 per share in early July.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven.

Evidence & confidence

The filing is a primary-source insider transaction, but the article provides no new operational, clinical, or financial information beyond the purchase details.

Market effects

No sector-level read-across; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or driven by liquidity/compensation needs, especially without a 10b5-1 plan.

Key entities

  • Palisade Bio, Inc.

    Company whose director insider purchase is disclosed on Form 4.

  • Baltera Robert Jr.

    Director who purchased 50,000 shares across two trades at about $2.04/share.

Related articles